Danaher Co. (NYSE:DHR) Shares Acquired by Hengehold Capital Management LLC

Hengehold Capital Management LLC boosted its holdings in Danaher Co. (NYSE:DHR) by 11.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,796 shares of the conglomerate’s stock after acquiring an additional 180 shares during the period. Hengehold Capital Management LLC’s holdings in Danaher were worth $499,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Oak Thistle LLC purchased a new stake in shares of Danaher during the second quarter worth about $363,000. Norden Group LLC purchased a new position in shares of Danaher during the 1st quarter worth $4,151,000. Duality Advisers LP purchased a new stake in shares of Danaher in the first quarter valued at $5,573,000. Investment Research & Advisory Group Inc. acquired a new position in Danaher in the first quarter valued at $1,186,000. Finally, Diversified Trust Co lifted its position in Danaher by 75.4% during the second quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock worth $1,090,000 after buying an additional 1,874 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Barclays lifted their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Stifel Nicolaus upped their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Danaher in a report on Friday, September 6th. Finally, Bank of America upped their price target on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $282.12.

Insiders Place Their Bets

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 in the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $276.50 on Thursday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The stock has a market cap of $204.80 billion, a P/E ratio of 45.42, a PEG ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a 50-day moving average of $270.53 and a two-hundred day moving average of $259.65.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the firm earned $2.05 EPS. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. On average, research analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.